linkedin
Anuj Gupta

Anuj Gupta

1 Lead - Healthcare ET Prime

A dental surgeon by training, I have worn many hats including that of a business consultant and now a journalist. At ET Prime, I will write on disruptors in healthcare and life sciences. Earlier, I worked with EY, helping global healthcare companies provide better care to their patients. Last-mile delivery of health services and innovation in medical technology are ideas that excite me. I feel healthcare stories in the media often tend to be too complex. My goal will be to simplify them, since healthcare isn’t a subject that should be restricted to experts. Food and motorcycling fuel me when I am not at work.

Twitter: @anujreports | Email: anuj.gupta1@timesinternet.in

A dental surgeon by training, I have worn many hats including that of a business consultant and now a journalist. At ET Prime, I will write on disruptors in healthcare and life sciences. Earlier, I worked with EY, helping global healthcare companies provide better care to their patients. Last-mile delivery of health services and innovation in medical technology are ideas that excite me. I feel healthcare stories in the media often tend to be too complex. My goal will be to simplify them, since healthcare isn’t a subject that should be restricted to experts. Food and motorcycling fuel me when I am not at work.

Twitter: @anujreports | Email: anuj.gupta1@timesinternet.in

Deals

Ab Dilli door nahi: Ranjan Pai is paying a hefty price for Medanta to break his northern jinx

After multiple unsuccessful attempts to break into the critical north Indian market, Manipal is placing a seemingly expensive bet on Medanta. Manipal’s investors are nearing their exit windows, increasing the pressure on the company to deliver returns. Other prominent hospital chains, including NH and HCG, have taken the same route in an industry struggling for growth.

7 Jun 20190 comment
Pharma

How policies choked small pharma

Unhelpful banks, long delays in getting GST refunds from the government, and measures designed to suit bigger players are sucking the air out of the sector.

16 Aug 20180 comment
Disputes

Sankyo-Daiichi's move to block Fortis's sale surprised us: Fortis chairman Ravi Rajagopal

When Malaysia’s IHH Healthcare Berhad won the bid for Fortis, the hospital chain expected an end to months of turmoil. Its relief was short-lived. Daiichi Sankyo, the Japanese firm that is fighting an arbitration battle related to Ranbaxy against Shivinder and Malvinder Singh — former promoters of both Ranbaxy and Fortis — wants the Delhi High Court to block Fortis’s sale. In his first interview after being appointed chairman, Ravi Rajagopal opens up about this unexpected hurdle and what it means for Fortis’s future.

8 Aug 20180 comment
Disputes

Can the Fortis-IHH deal overcome "surprise" Daiichi roadblock?

Daiichi-Sankyo wants Delhi High Court to block Fortis’s sale to IHH pending the recovery of its dues from the Singh brothers. Fortis chairman Ravi Rajagopal says Daiichi’s action is unexpected, but hopes it will have no bearing on the deal. Is there a final twist left in this unending tale?

8 Aug 20180 comment
Leadership

The knights of IHH

After a treacherous few months, which included two early losses to rival bidders, IHH Healthcare Berhad of Malaysia is set to take Fortis home. Who are the architects of what has been possibly the most nerve-racking deal in Indian healthcare history?

10 Jul 20180 comment
Under the lens

Why the queue of suitors for Fortis is thinning

The Munjal-Burman alliance, Fortis’s most gung-ho bidder not so long ago, has given up on it. A close look at financial and legal documents reveals the mess that is taking the sheen off one of Indian healthcare’s biggest brands.

5 Jul 20180 comment
R&D

Superbugs have designs on India. Our preparation is inadequate.

Anti-microbial resistance (AMR) is a threat that is growing in severity. The country needs to develop better tests for early diagnosis, educate patients and doctors to not overuse antibiotics, and invest in new-generation antibiotics. At the moment, it is doing too little in all three areas.

3 Jul 20180 comment
Hospitals

The humans of Fortis

Amid the endless scandals and doomsday rumours, this is the story that has never been told: of how a bunch of professionals is keeping India’s most troubled hospital chain alive.

8 Jun 20180 comment
Policy and regulations

Stem cells: minimum manipulation, maximum confusion

Should stem-cell treatment be described as a drug or a therapy? The question, following a health ministry draft note, has perplexed stakeholders of all hues — from the regulatory agency and research body to practising doctors — who are all pulling in different directions.

15 May 20180 comment
[[^message]]

Result

[[/message]] [[#message]]

[[message]]

[[/message]]